Shares in Novo Nordisk fell at opening on Friday, after the Wegovy-maker and rival Eli Lilly struck a deal late on Thursday with U.S. President Donald Trump to slash prices of their GLP-1 weight-loss ...

As demand for Ozempic, Wegovy and Zepbound grows, local patients say cost remains the biggest barrier ...

In the Oval Office today, the president announced that he had secured a deal to dramatically slash the price of obesity drugs ...

Dow Jones Top Company Headlines at 1 AM ET: Tesla Shareholders Approve Elon Musk's $1 Trillion Pay Package | Trump ... The new package, which includes 12 chunks of stock, could give Musk control over ...

The White House’s weight-loss drug briefing was halted after Novo Nordisk executive Gordon Findlay fainted on camera, ...

Oz acknowledged obesity isn't "a deficiency of GLP drugs" but called reducing costs "a belt-and-suspenders approach." ...

The drugs are part of a new generation of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Dow Jones Top Company Headlines at 11 PM ET: OpenAI CEO Says U.S. Shouldn't Bail Out AI Companies | Blackstone ... The comments come after OpenAI's chief financial officer discussed the role of ...

President Donald Trump is adjusting his messaging strategy to win over voters who are worried about the cost of living with ...

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) reported a rise in third-quarter revenue and earnings but surprised ...

President Donald Trump promises lower prices for weight loss drugs and reveals, one of his key staff members has a ...

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy ...